Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients.
Colorectal cancer
fluoropyrimidine
immune-related-gene
tumor-infiltrating immune cells
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
19 10 2020
19 10 2020
Historique:
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
Fluoropyrimidine-based chemotherapy is an essential component of systemic chemotherapy for colorectal cancer (CRC). The immune response is implicated in chemotherapy-induced cytotoxicity. Here, we reported an immune risk (Imm-R) model for prognostic prediction in patients receiving fluoropyrimidine-based chemotherapy. Gene expression profiles and corresponding clinical information were collected from four data sets and divided into training set (n = 183) and validation set (validation set1: n = 34; validation set2: n = 99). The composition of 22 tumor-infiltrating immune cells (TIICs) populations was characterized with the CIBERSORT deconvolution algorithm. A prognostic Imm-R model for predicting overall survival was established by performing least absolute shrinkage and selection operator (LASSO) penalized COX regression analysis. T follicular helper cells and M0 macrophages were associated with better survival, while eosinophils were associated with worse survival. TIICs signature was constructed based on the above three immune cell types. Furthermore, a Imm-R model was created by integrating TIICs signature with immune-related genes (IRGs), which effectively in distinguishing CRC patients with poorer prognosis. The Imm-R model was associated with activation of the TGF-beta signaling and suppression of DNA damage. Results of this research provide new insights into the role of immunity for in fluoropyrimidine-based chemotherapy as well as a useful tools to predict the outcome of CRC patients receiving fluoropyrimidine-based chemotherapy.
Identifiants
pubmed: 33117604
doi: 10.1080/2162402X.2020.1832347
pii: 1832347
pmc: PMC7575007
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1832347Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Cancer. 2015 Feb 15;121(4):527-34
pubmed: 25332117
Front Immunol. 2019 Jul 17;10:1654
pubmed: 31379850
Lancet. 2007 Dec 15;370(9604):2020-9
pubmed: 18083404
Oncoimmunology. 2017 Jul 12;6(12):e1342918
pubmed: 29209561
Ann Surg. 2020 Jun 04;:
pubmed: 32511132
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Front Immunol. 2019 Jul 24;10:1713
pubmed: 31396225
Immunol Cell Biol. 2014 Jan;92(1):64-71
pubmed: 24145858
JCO Precis Oncol. 2018 Jun 13;2018:
pubmed: 30088816
Br J Cancer. 2004 Nov 1;91(9):1711-7
pubmed: 15494715
Biomed Pharmacother. 2019 Oct;118:109228
pubmed: 31351430
Science. 2012 Sep 28;337(6102):1678-84
pubmed: 23019653
Oncoimmunology. 2019 Apr 15;8(7):1596715
pubmed: 31143520
Cancer Med. 2018 Sep;7(9):4496-4508
pubmed: 30117315
Onco Targets Ther. 2019 Apr 18;12:3051-3063
pubmed: 31114248
Clin Cancer Res. 2018 Jan 1;24(1):224-233
pubmed: 29061646
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Int J Cancer. 2018 Nov 1;143(9):2271-2280
pubmed: 29873076
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Trends Cancer. 2016 Nov;2(11):664-675
pubmed: 28741505
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Mod Pathol. 2016 Nov;29(11):1433-1442
pubmed: 27443512
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Exp Cell Res. 2018 Nov 1;372(1):35-42
pubmed: 30205088
Acta Oncol. 2016 Dec;55(12):1425-1433
pubmed: 27435662
Eur J Cancer. 2017 May;76:68-75
pubmed: 28284171
Oncogene. 2008 Jan 3;27(1):85-97
pubmed: 17599042
Int J Oncol. 2007 Dec;31(6):1491-500
pubmed: 17982676
J Clin Oncol. 2004 Aug 15;22(16):3408-19
pubmed: 15199089
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
Oncoimmunology. 2018 Mar 6;7(6):e1433517
pubmed: 29872564
J Oncol. 2012;2012:608406
pubmed: 22927846
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Biom J. 2010 Feb;52(1):70-84
pubmed: 19937997
Trends Cancer. 2015 Sep 1;1(1):66-75
pubmed: 26457331
J Exp Med. 1998 Dec 21;188(12):2357-68
pubmed: 9858522
Biomed Res Int. 2019 Sep 30;2019:5953619
pubmed: 31662984
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Mol Sci. 2017 Oct 24;18(10):
pubmed: 29064420
Mol Cancer. 2016 Aug 24;15(1):55
pubmed: 27552968
Curr Med Chem. 2016;23(7):650-66
pubmed: 26785997
J Exp Med. 2000 Dec 4;192(11):1545-52
pubmed: 11104797
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Neoplasma. 2014;61(2):177-85
pubmed: 24063790
Pharmacol Ther. 2020 Feb;206:107447
pubmed: 31756363
Sci Data. 2018 Feb 27;5:180015
pubmed: 29485622
PLoS Med. 2016 Dec 13;13(12):e1002194
pubmed: 27959923
Br J Cancer. 2018 May;118(10):1322-1328
pubmed: 29695770
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Oncotarget. 2016 Dec 6;7(49):81144-81155
pubmed: 27835894
J Immunother Cancer. 2019 May 22;7(1):131
pubmed: 31113486
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32719094
Oncotarget. 2017 Dec 27;9(5):6201-6212
pubmed: 29464065
Hum Immunol. 2011 Nov;72(11):1022-8
pubmed: 21884745
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Oncol. 2010 May;21 Suppl 5:v93-7
pubmed: 20555112
Cell Oncol (Dordr). 2020 Dec;43(6):1203-1214
pubmed: 32797385
Genome Biol. 2013 Apr 29;14(4):R34
pubmed: 23618380
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Surg Oncol. 2020 Oct;46(10 Pt B):e62-e70
pubmed: 32863096
BMC Cancer. 2014 Feb 05;14:64
pubmed: 24495478
Ageing Res Rev. 2020 Aug;61:101071
pubmed: 32344191
Mod Pathol. 2016 May;29(5):516-27
pubmed: 26916075
Nat Rev Immunol. 2015 Mar;15(3):185-9
pubmed: 25677493
N Engl J Med. 2018 Dec 13;379(24):2330-2341
pubmed: 30380364
Sci Rep. 2019 Sep 17;9(1):13455
pubmed: 31530839